Abstracts tagged "corticosteroids"

Abstract Number: 1642 • ACR Convergence 2021
Baseline Body-mass-index and Risk for Obesity in Children with Rheumatic Disease on Moderate to High-dose Prednisone Therapy
Roberta Berard¹, Michael Rieder², Erkan Demirkaya², Michael Miller³ and Renee Pang², ¹London Health Sciences Centre, London, ON, Canada, ²University of Western Ontario, London, ON, Canada, ³University of Western Ontario, Children's Research Institute, London, ON, Canada
Background/Purpose: Prednisone is a glucocorticoid (GC) medication commonly used in moderate ( >7.5 mg per day) to high doses (≥ 1 mg/kg/day) for children with…
Abstract Number: 1678 • ACR Convergence 2021
Favorable Balance of Benefit and Harm of Long-Term, Low Dose Prednisolone Added to Standard Treatment in Rheumatoid Arthritis Patients Aged 65+: The Pragmatic, Multicenter, Placebo-Controlled GLORIA Trial
Maarten Boers¹, Linda Hartman¹, Daniela Opris-Belinski², Reinhard Bos³, Marc Kok⁴, Jose Pereira da Silva⁵, Ed Griep⁶, Ruth Klaasen⁷, Cornelia F. Allaart⁸, Paul Baudoin⁹, Hennie Raterman¹⁰, Zoltan Szekanecz¹¹, Frank Buttgereit¹², Pavol Masaryk¹³, L. Thomas Klausch¹, Sabrina Paolino¹⁴, Annemarie Schilder³, Willem Lems¹⁵ and Maurizio Cutolo¹⁴, ¹Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ²Carol Davila University, Bucharest, Romania, ³Medical Center Leeuwarden, Leeuwarden, Netherlands, ⁴Maasstad Hospital, Rotterdam, Netherlands, ⁵University of Coimbra | UC · Clínica Universitária de Reumatologia. Faculty of Medicine, Columbia, Portugal, ⁶Antonius Hospital, Sneek, Netherlands, ⁷Meander Medical Center, Amersfoort, Netherlands, ⁸Leiden University Medical Center, Leiden, Netherlands, ⁹Reumazorg Flevoland, Emmeloord, Netherlands, ¹⁰Northwest Clinics, Alkmaar, Netherlands, ¹¹Division of Rheumatology, University of Debrecen, Faculty of Medicine, Debrecen, Hungary, ¹²Charité – Universitätsmedizin Berlin, Berlin, Germany, ¹³National Institute for the Rheumatic Diseases, Bratislava, Slovakia, ¹⁴Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa, Italy, ¹⁵VUmc, Amsterdam, Netherlands
Background/Purpose: Low-dose glucocorticoid (GC) therapy is widely used in rheumatoid arthritis (RA) but the balance of benefit and harm is still unclear. We studied the…
Abstract Number: 1735 • ACR Convergence 2021
Glucocorticoid Discontinuation in Patients with Systemic Lupus Erythematosus with Prior Severe Organ Manifestation
Takehiro Nakai¹, Futoshi Iwata¹, Genki Kidoguchi¹, Sho Fukui², Hiroki Ozawa¹, Satoshi Kawaai³, Yukihiko Ikeda¹, Ayako Koido⁴, Masei Suda⁵, Atsushi Nomura⁶, Hiromichi Tamaki¹, Kenichi YAMAGUCHI¹ and Masato Okada¹, ¹St. Luke's International Hospital, Tokyo, Japan, ²Immuno-Rheumatology Center, St. Luke’s International Hospital, and Center for clinical epidemiology, St. Luke’s International University, Tokyo, Japan, ³Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, Chuo-ku, Tokyo, Japan, ⁴St. Luke's International Hospital, Akashi-cho, Chuo-ku, Tokyo, Japan, ⁵Suwa Central Hospital, Nagano, Japan, ⁶St. Luke's International Hospital, Nagareyama, Japan
Background/Purpose: Most long-term damage in systemic lupus erythematosus (SLE) has been attributed to continuous glucocorticoid use; however, glucocorticoid discontinuation is occasionally associated with disease flare-ups.…
Abstract Number: 1914 • ACR Convergence 2021
Immunomodulatory and Immunosuppressive Medication Modification Among Rheumatology Patients at the Time of COVID-19 Vaccination
Jonah Levine¹, Deanna Jannat-Khah¹, Vivian Bykerk², Lisa Mandl¹ and Medha Barbhaiya¹, ¹Hospital for Special Surgery, New York, NY, ²Division of Rheumatology, Hospital for Special Surgery, New York City, NY
Background/Purpose: Due to concerns about underlying immune dysregulation and immunosuppression, patients with systemic rheumatic diseases (SRD) may have modified their medications at the time of…
Abstract Number: 0058 • ACR Convergence 2021
Effect of Anti-inflammatory Drugs on Intestinal Epithelial Damage and Bacterial Translocation in the Adjuvant-induced Arthritis Model
Sophie Hecquet¹, Perle Totoson², Maude Tournier², Clement Prati¹, Daniel Wendling¹, Céline Demougeot² and Frank Verhoeven¹, ¹Service de rhumatologie, CHU de Besançon, Besançon, France, ²PEPITE EA4267, FHU INCREASE, Bourgogne Franche-Comté University, Besançon, France
Background/Purpose: The intestine is no longer considered as an organ targeted by spondyloarthritis (SpA) but also an actor of the disease alongside environmental and immunological…
Abstract Number: 0111 • ACR Convergence 2020
Assessment and Treatment of Glucocorticoid-Induced Osteoporosis in a Rheumatology Clinic
Amanda Stefl¹, Shikha Singla², Jessica Michaud¹, Kama Thomas², Lisa Rein² and Mary Ellen Csuka², ¹Froedtert Hospital, Milwaukee, WI, ²Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Glucocorticoids (GC) are used as a long-term treatment option for an estimated 1% of the US population. The American College of Rheumatology has maintained…
Abstract Number: 0113 • ACR Convergence 2020
Improving Glucocorticoid-Induced Osteoporosis Screening and Management in Patients with Rheumatic Diseases Using the 2017 ACR Guidelines
Marielys Figueroa Sierra¹, Atefeh Vafa¹, Shu Cao², Yuanyuan Lu³, Helen Bateman⁴, John Carter¹, Yih Chang Lin², Raquel Cuchacovich¹, Marcos Maldonado⁴, Joanne Valeriano-Marcet¹ and Gabriela Montes-Rivera⁴, ¹University of South Florida, Tampa, FL, ²University of South Florida, Morsani College of Medicine, Tampa, FL, ³Biostatistician at Graduate Medical Education Department, Tampa, FL, ⁴James A. Haley VA, Tampa, FL
Background/Purpose: Glucocorticoid-induced osteoporosis (GIOP) is a potentially preventable complication in those who are maintained on glucocorticoid (GC) therapy. It is imperative to identify these patients…
Abstract Number: 0404 • ACR Convergence 2020
Isolated Aortitis: Single Centre Experience of Clinical Spectrum and Management
Nadia Ahmad¹, Ayna Verdiyeva², Raashid Luqmani² and Shirish Dubey², ¹Oxford University Hospitals NHS Foundation Trust, Reading, United Kingdom, ²Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
Background/Purpose: Aortitis was previously regarded as a rare form of large vessel vasculitis (LVV), but is now increasingly being recognised. It may occur in the…
Abstract Number: 0466 • ACR Convergence 2020
Dosage Modification of Immunomodulatory Medications by Rheumatology Patients in New York City During the Peak of the COVID-19 Pandemic
Marianna Frey¹, Gregory Vitone², Candace Feldman³, Lindsay Lally¹, Anne Bass⁴, Jane Salmon¹, Mary Crow¹, Michael Lockshin⁵, Vivian Bykerk¹, Lisa Mandl¹ and Medha Barbhaiya⁵, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, ³Brigham and Women's Hospital, Boston, ⁴Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY
Background/Purpose: Due to concerns about underlying immune dysregulation and immunosuppression, patients with systemic rheumatic diseases living in COVID-19 “hot spots” may have modified their immunomodulatory…
Abstract Number: 0872 • ACR Convergence 2020
Usage of Corticosteroids and Hospitalisation Duration in Adult Patients with Systemic Lupus Erythematosus (SLE) in Latvia
Ilze Vinkalna¹, Inita Bulina², Natalija Vellere², Kristine Ivanova², Pauls Rubins², Renate Diura², Santa Mikena², Julija Zepa² and Daina Andersone², ¹Pauls Stradins Clinical University Hospital, Rīga, Latvia, ²Pauls Stradins Clinical University Hospital, Riga
Background/Purpose: To determine the factors influencing hospitalisation duration, re – hospitalisation (more than 1 hospitalisation during the study period), frequency of the usage of corticosteroids…
Abstract Number: 1014 • ACR Convergence 2020
Disease Modifying Anti-rheumatic Drugs, Biologics and Corticosteroid Use in Older Patients with Rheumatoid Arthritis over 20 Years
John Hanly¹ and Lynn Lethbridge², ¹Dalhousie University, Halifax, NS, Canada, ²Dalhousie University, Halifax, Canada
Background/Purpose: The objective of the current study was to examine the change in prescribing patterns for older adults with RA over a 20 year period…
Abstract Number: 1569 • ACR Convergence 2020
Immune Related Adverse Events Related to Check Point Inhibitors Among Outpatients in an Academic Center
Bushra Akram¹, Aleena Itani¹, Mohammad Razaq², Samera Vaseer¹, Sara Vesely¹ and Pawan Acharya¹, ¹University of Oklahoma Health Sciences Center, Oklahoma City, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Immune check point inhibitors (ICIs) allow the body to recognize tumor cells as non-self, resulting in immune-cell mediated tumor cell destruction. These therapies have the…
Abstract Number: 1571 • ACR Convergence 2020
Distinct T Cell Responses in Inflammatory Arthritis Associated with Combined CTLA-4 and PD-1 Inhibitor Therapy
Sang Kim¹, Jean Tayar², Maria Suarez-Almazor³, Huifang Lu⁴, Yang-Zhi Zhao⁵, Margarita Divenko⁵, William Padron⁵, Emma Rodriguez⁵, Sattva Neelapu⁵, Jennifer Wang⁵, Amish Shah⁵, Nizar Tannir⁵, Don Gibbons⁵, Guillermo Garcia-Manero⁵, Hussein Tawbi⁵, Patrick Hwu⁵, Andrew Futreal⁵, Adi Diab⁵ and Roza Nurieva⁵, ¹The Univesrity of Texas MD Andesron Cancer Center, Pearland, TX, ²The University of Texas, MD Anderson Cancer Center, Houston, TX, ³University of Texas MD Anderson Cancer Center, Houston, TX, ⁴MD Anderson, Houston, TX, ⁵MD Anderson, Houston
Background/Purpose: Despite of unprecedented clinical success in cancer therapeutics, immune checkpoint inhibitors (ICIs) are associated with immune-related adverse events (irAEs), including arthritis (arthritis-irAE). Arthritis-irAE can…
Abstract Number: 1625 • ACR Convergence 2020
Pneumocystis Jiroveci Pneumonia in Immunocompromised Patients with Rheumatologic Disease in a Single, Tertiary Medical Center
Zahra Rehman¹, Megan Krause¹, Jessica Newman² and Pooja Bhadbhade¹, ¹The University of Kansas Medical Center, Kansas City, KS, ²The University of Kansas Medical Center, Kansas City
Background/Purpose: Pneumocystis jiroveci pneumonia (PJP) is rare, but can be fatal among immunocompromised. There is no consensus on indications for PJP prophylaxis in rheumatologic patients.…
Abstract Number: 1650 • ACR Convergence 2020
A Double-Blind Randomized Trial to Evaluate the Efficacy of Corticosteroid Injections for Osteoarthritis of the Knee Using Mobile Devices
Joshua Baker¹, Mitesh Patel¹, Tuhina Neogi², Keith Robinson³, Alexis Ogdie¹ and Carla Scanzello¹, ¹University of Pennsylvania, Philadelphia, PA, ²Boston University School of Medicine, Boston, MA, ³Corporal Michael J Crescenz VA Medical Center, Philadelphia, PA
Background/Purpose: The value of intra-articular (IA) corticosteroid injections for osteoarthritis of the knee (KOA) has recently been called into question. Variability in clinical trial design…

« Previous Page
1
…
4
5
6
7
8
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].